CLN-081 has demonstrated an encouraging response rate along with a manageable safety profile in heavily pretreated advanced NSCLC patients with EGFR insertion20.

Roche is expected to announce the pivotal expansion findings of the leading bispecific antibody in DLBCL, while Seagen is expected to announce the safety and efficacy data of a prospective ADC for DLBCL treatment.

Both AbbVie and Roche are geared up for data readout of their respective bispecific antibodies, whereas Beigene will provide the primary analysis of the ROSEWOOD trial. Lastly, Incyte is expected to offer trial in-progress updates for tafasitamab from the inMIND study.

Novartis is set to present a subgroup analysis of its already approved radioligand therapy in mCRPC, where Point Biopharma is the next entrant. To bank on its effectiveness as a chemotherapeutic agent in mCRPC, Modra Pharmaceuticals is focusing on bringing oral docataxel to the market. At the same time, Veru Pharma is geared up to present the final analysis of sabizabulin.

Gilead Science’s Trodelvy and AstraZeneca’s Enhertu met primary endpoints in HR+/HER2- advanced breast cancer and HER2 low breast cancer, respectively. After the failure of Sanofi’s Amcenestrant in the AMEERA-3 trial, we look forward to what the company has to present in the AMEERA-4 trial. Furthermore, Eli Lilly is all set to present the results of imlunestrant in ESR1 mutation in ER+/HER2− breast cancer patients.

Mirati all set to present adagrasib’s registration enabling results from KRYSTAL-1 study, on the contrary, Roche is disappointed with Phase III SKYSCRAPER-02 study results.